Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?

Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?

Submitted by admin on October 29, 2023 - 8:44pm
Source: 
Motley Fool
News Tags: 
Roche
Eli Lilly
Pfizer
IBD
ulcerative colitis
Crohn's Disease
mirikizumab
Headline: 
Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?
snippet: 
  • Roche spent $7.1 billion on a company, primarily because of an IBD therapy.
  • Pfizer just got approval for a pill to treat ulcerative colitis.
  • Eli Lilly just reported promising trial data for its IBD therapy, mirikizumab.

Do Not Allow Advertisers to Use My Personal information